Biotech Startups

Joywell Foods (Oobli) produces sweet proteins found in rare fruits and berries that taste like sugar but digest like protein, and can replace up to 90% of sugar in products such as beverages and baked goods. It supplies these ingredients to food companies as an alternative sweetener.

1 investor

A blog-style page discussing laboratory testing and nutritional value analysis of dietary supplements, aimed at supplement manufacturers seeking to verify product label claims. The content covers quality assurance and laboratory verification of nutrient and bioactive ingredient content.

1 investor

JSLink is a biotechnology company specializing in genomic analysis services and personalized medicine, with growing operations in rare-earth permanent magnet manufacturing. The company combines genomics research with biomarker discovery and bioinformatics analysis to support drug development and personalized medical treatment.

1 investor

P95 Julius Clinical is a contract research organization that conducts clinical trials and real-world evidence programs for biotech and pharmaceutical companies, with expertise in neuroscience, infectious diseases, vaccines, and cardiovascular and metabolic diseases. The company operates globally across 25+ countries with over 500 professionals.

1 investor

Junction Bioscience develops AI-driven software that generates and tests scientific hypotheses to discover new drug candidates, with an initial focus on therapies targeting neuroinflammatory and immunological diseases.

1 investor

Junevity is a biotech company developing siRNA therapeutics based on its RESET platform, which uses transcription factor repression to restore healthy gene expression and target age-related diseases. The company applies bioinformatics, machine learning, and cellular aging research to develop treatments for metabolism and aging-related conditions.

1 investor

A biosciences company combining targeted diagnostics and therapeutic delivery to improve outcomes in oncology.

1 investor

Juniper Biomedical develops minimally invasive implantable medical devices using neuromodulation technology to treat pelvic health conditions. The company addresses unmet clinical needs in urinary incontinence and other pelvic floor disorders for patients and healthcare providers.

1 investor

Seattle CAR-T and TCR cancer immunotherapy company founded in 2013 and acquired by Celgene for $9 billion in 2018.

1 investor

1 investor

K2 Therapeutics is a biotech company that identifies innovative drug assets and develops them into medicines using a hub-and-spoke model with cross-regional clinical trials. Its pipeline focuses on first- and best-in-class cell therapies for solid tumors, including a PRAME-targeting therapy for cutaneous melanoma and synovial sarcoma.

1 investor

K2bio operates a fully equipped, AAALAC-accredited contract vivarium facility in Houston supporting preclinical research for biotechnology and pharmaceutical companies. The facility provides flexible access to animal housing, technical services, imaging systems, and expertise across multiple therapeutic modalities including biologics, small molecules, and cell therapies.

1 investor

Kaffe Bueno upcycles coffee by-products into functional ingredients for consumer and industrial applications, operating as a sustainable biotech company focused on circular economy principles.

1 investor

Kaigene is a Maryland biotechnology company developing therapeutic antibodies and fusion proteins for rare autoimmune diseases.

1 investor

Kailos Genetics is a biotechnology company with expertise in medical and biotechnology industries.

1 investor

Kalevala Therapeutics identifies drug repurposing opportunities for rare disease indications, aligning with clinical and advocacy partners to map regulatory pathways and pursue approval for new therapeutic uses. It operates in the biotech and drug development sector.

1 investor

Kalexo Bio develops dual-targeting siRNA therapeutics for cardiovascular disease, with a focus on lipid management and atherosclerotic disease prevention. The company's lead program targets genetic drivers of cardiovascular risk to deliver durable risk reduction in patients.

1 investor

Kalion manufactures high-purity glucaric acid and glucuronic acid for use as corrosion inhibitors, polymer additives, and ingredients in pharmaceuticals, nutraceuticals, and energy drinks. The company serves formulators and manufacturers across cleaning, concrete, water treatment, polymers, and pharmaceutical applications.

1 investor

KaliVir Immunotherapeutics develops oncolytic viral immunotherapies for the treatment of advanced solid tumors, including its VET3-TGI candidate being evaluated in combination with checkpoint inhibitors. The company operates in the immuno-oncology and biotechnology sector.

1 investor

Kamada is a vertically integrated biopharmaceutical company that develops and manufactures plasma-derived therapeutics for specialty markets. The company commercializes its own branded products including GLASSIA and KEDRAB, as well as acquired hyperimmune products, distributing to over 30 countries globally.

1 investor

Kaminari Medical develops intravascular imaging technology for cardiovascular interventions, using photoacoustic and optical innovations. The company serves interventional cardiologists and vascular surgeons for real-time imaging during catheter-based procedures.

1 investor

Kanjin Therapeutics is a biotechnology startup developing treatments to restore kidney function and address chronic kidney diseases, using a strategy of targeting the liver. Founded as a scientific spinout from Okayama University, it operates across the US and Japan.

1 investor

Kardium develops the Globe Pulsed Field System, an all-in-one cardiac ablation catheter with 122 individually selectable electrodes that combines high-density mapping and pulsed field ablation. It is designed for physicians treating patients with atrial fibrillation.

1 investor

Karydo TherapeutiX (KarydoTX) develops a "Precision Human Digital-Twins System" (Precision hDTS) that measures molecular, cellular, organ, and inter-organ information in real time to create a live digital twin of the body, predicting future conditions to enable early detection, prevention, and treatment of disease. The company aims to contribute to a society of healthy longevity through this integrated, individually customized system.

1 investor